Nycomed/Diatide Will Promote NeoTect As Less Invasive Than Lung Biopsy
Executive Summary
Nycomed Amersham and marketing partner Diatide will promote NeoTect as a less invasive means of distinguishing malignant from benign lung mass compared to needle biopsy and lung surgery, which are more painful and produce higher rates of complications compared to NeoTect, the companies said.